Brief: Pharnext To Begin Last PXT3003 Phase III Study Before End Q1-21
10/06/2020 06:13
June 10 (Reuters) - PHARNEXT SA PHARN.PA :
* PHARNEXT PROVIDES REGULATORY AND CLINICAL UPDATE ON
PXT3003
PHASE III STUDY FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH TYPE 1A
* PLANS TO INITIATE FINAL PIVOTAL PHASE III CLINICAL STUDY
BEFORE
END OF Q1 2021
* US FOOD AND DRUG ADMINISTRATION HAS AGREED WITH PHARNEXT
AND
PROVIDED CLEAR GUIDANCE ON REGULATORY PATHWAY TO APPROVAL FOR
PXT3003
Source text for Eikon: ID:nEQ727ff4a
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development